APPLICATION
NDA017806
TYPE
NDA
ORIGINAL APPROVAL
1977-12-16
LATEST ACTION
2011-08-25
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
THALLOUS CHLORIDE TL 201 · ReferenceDiscontinued
THALLOUS CHLORIDE TL-201 2mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INTRAVENOUS
THALLOUS CHLORIDE TL 201 · ReferenceDiscontinued
THALLOUS CHLORIDE TL-201 1mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
Approval history
1998-10-09Manufacturing (CMC) · Supplement 24 · priorityAP
1997-03-07Labeling · Supplement 23 · standardAP
1995-02-24Efficacy · Supplement 22AP
1986-12-09Efficacy · Supplement 20AP
1986-12-09Efficacy · Supplement 21AP
1984-03-15Labeling · Supplement 19AP
1983-03-10Manufacturing (CMC) · Supplement 17 · priorityAP
1983-03-08Manufacturing (CMC) · Supplement 18 · priorityAP
1983-02-22Manufacturing (CMC) · Supplement 16 · priorityAP
1982-10-18Manufacturing (CMC) · Supplement 15 · priorityAP
1982-09-14Manufacturing (CMC) · Supplement 13 · priorityAP
1982-02-08Manufacturing (CMC) · Supplement 9 · priorityAP
1981-12-31Labeling · Supplement 12AP
1981-04-30Manufacturing (CMC) · Supplement 10 · priorityAP
1981-04-25Manufacturing (CMC) · Supplement 11 · priorityAP
1979-12-26Manufacturing (CMC) · Supplement 8 · priorityAP
1979-04-19Manufacturing (CMC) · Supplement 6 · priorityAP
1979-04-12Manufacturing (CMC) · Supplement 5 · priorityAP
1978-08-11Manufacturing (CMC) · Supplement 3 · priorityAP
1978-08-11Manufacturing (CMC) · Supplement 2 · priorityAP
1978-07-14Manufacturing (CMC) · Supplement 1 · priorityAP
1977-12-16Type 1 - New Molecular Entity · Original · priorityAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.